<div class="infobox infobox-company">
<div class="infobox-header">Johnson & Johnson</div>
<div class="infobox-row"><strong>Headquarters:</strong> New Brunswick, New Jersey, USA</div> [@immune]
<div class="infobox-row"><strong>Founded:</strong> 1886</div> [@clinicaltrialsgov]
<div class="infobox-row"><strong>Market Cap:</strong> ~$380 billion (2024)</div> [@jnj]
<div class="infobox-row"><strong>Ticker:</strong> JNJ (NYSE)</div>
<div class="infobox-row"><strong>Division:</strong> Janssen Pharmaceuticals</div>
<div class="infobox-row"><strong>Website:</strong> [jnj.com](https://www.jnj.com)</div>
</div>
Funding
- IPO: 1944 (NYSE: JNJ)
- Market Cap: ~$400B (2026)
- 2025 Revenue: $85B
- 2024 Revenue: $88B
- R&D Investment: ~$15B annually
- Recent M&A:
- Abiomed (2022): $16.6B
- Momenta (2020): $6.5B
Overview
Mermaid diagram (expand to render)
Johnson & Johnson, through its Janssen Pharmaceutical Companies, is a major player in neurodegenerative disease research and development. The company has been actively developing therapies for Alzheimer's disease, Parkinson's disease, and other CNS disorders. Janssen's neuroscience portfolio combines small molecule approaches with antibody therapies, often developed through strategic collaborations with biotechnology partners.
Alzheimer's Disease Pipeline
Tau Targeting Programs
| Compound | Mechanism | Phase | Status |
|----------|-----------|-------|--------|
| JNJ-63733657 | Anti-[tau](/proteins/tau) antibody | Phase 2 | Ongoing |
| JNJ-63733657 + ACI-35 | Tau vaccine collaboration | Phase 1b/2a | With AC Immune |
Janssen's tau antibody program targets pathological tau aggregates, which are a hallmark of Alzheimer's disease and other tauopathies. The company's collaboration with [AC Immune](/companies/ac-immune) has yielded multiple therapeutic candidates targeting different tau epitopes.
Beta-Secretase (BACE) Programs
Janssen previously investigated BACE inhibitors for Alzheimer's disease, but these programs were discontinued following industry-wide setbacks with this mechanism. The company has since pivoted toward alternative approaches including tau immunotherapy and neuroinflammation targets.
Neuroinflammation
Janssen is exploring modulation of neuroinflammatory pathways as a therapeutic approach for AD. This includes targeting microglial activation and complement pathways that contribute to neurodegeneration.
Parkinson's Disease Programs
| Compound | Mechanism | Phase | Status |
|----------|-----------|-------|--------|
| JNJ-40411813 | mGluR2 positive modulator | Discontinued | - |
| Parkinson's gene therapy | AAV-based delivery | Preclinical | Research |
Janssen has explored multiple mechanisms for Parkinson's disease treatment, including glutamate modulation and gene therapy approaches. The company's gene therapy programs leverage expertise from its broader AAV platform capabilities.
Antibody Engineering
Janssen utilizes advanced antibody engineering platforms for developing therapeutic antibodies targeting CNS antigens. Their technologies include:
- Bispecific antibodies for enhanced target engagement
- Fc engineering for optimized effector function
- [Blood-brain barrier](/entities/blood-brain-barrier) transport technologies
Gene Therapy
The company has invested in AAV-based gene therapy platforms applicable to neurodegenerative diseases. This includes capabilities in vector design, manufacturing, and CNS delivery.
Key Collaborations
AC Immune Partnership
Janssen's collaboration with [AC Immune](/companies/ac-immune), initiated in 2015 and expanded in 2020, focuses on tau-targeting therapeutics:
- Anti-tau antibodies (JNJ-63733657)
- Active tau immunization (ACI-35 vaccine)
- Diagnostic imaging agents
Academic Partnerships
Janssen maintains research collaborations with leading academic institutions for neurodegenerative disease research, including programs at:
- [Alzheimer's Disease](/diseases/alzheimers-disease) Research Centers
- Movement Disorder Centers of Excellence
- Translational neuroscience programs
- 2023 R&D Spending: $14.6 billion (company-wide)
- Neuroscience R&D: Significant portion of pharmaceutical R&D budget
- Strategic Investment: Continued commitment to neuroscience pipeline
Key Personnel
- CEO: Joaquin Duato
- Chief Scientific Officer: Paul Stoffels (former)
- Janssen Neuroscience Leadership: Dedicated therapeutic area leadership team
Clinical Evidence
Janssen's Alzheimer's programs have generated clinical data including:
- Phase 1 safety and tolerability data for tau antibodies
- Biomarker data demonstrating target engagement
- Ongoing Phase 2 efficacy trials
Competitive Positioning
Janssen differentiates itself through:
Diversified Pipeline - Multiple mechanisms targeting AD and PD
Strategic Partnerships - Collaborations with leading biotech companies
Global Infrastructure - Worldwide clinical development capabilities
Technology Integration - Combining antibodies, gene therapy, and small moleculesSee Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [AC Immune](/companies/ac-immune)
- [Tau Protein](/proteins/tau)
- [Companies Index](/companies/index)
External Links
- [Johnson & Johnson Website](https://www.jnj.com/)
- [ClinicalTrials.gov](https://clinicaltrials.gov)
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
References
Unknown, Johnson & Johnson Annual Report 2023 (2023)
Unknown, Janssen Neuroscience Pipeline (n.d.)
Unknown, AC Immune and Janssen Tau Collaboration Press Release (n.d.)
Unknown, ClinicalTrials.gov - Janssen Alzheimer's Studies (n.d.)
Unknown, JNJ-63733657 Phase 2 Trial Information (n.d.)